Progressive CMV infections pose a major threat to transplant recipients. CD8 T cells are considered to be the primary control for CMV viremia. Sufficient levels of CMV-specific CD8 T cells are found to protect against CMV disease (see references 1,2). Current assays based on PCR and antigen-detection are capable of analysing the viral burden and detect a CMV-reactivation, however, any immunoreactivtity against CMV cannot be assessed.
The CMV-Tetramer Test provides for the first time a ready-to-use kit to quantify the number of CMV-specific CD8 T cells, thus helping the clinician to assess patients with high risk to develop CMV disease.
Expected benefits of monitoring the CMV-specific CD8 T cell number (see references 1-5):
1) Gratama & Cornelissen, Clin. Appl. Immun.Rev. 2001
2) Moss & Khan, Hum. Immun. 2004
3) Cwynarski et al. Blood 2001
4) Gratama et al. Blood 2001
5) Gratama et al., Cytometry B Clin. Cytom. 2008
Glycotope Biotechnology offers several clinical diagnostics and research reagents based on flow cytometry procedures for the fast and precise measurement of various cell functions focused on functional characterisation of the cellular immune reponse and characterisation of haematological relevant auto-immune disease.
We offer a range of flow cytometry-based assays for the analysis of the functional activity of
Clinical diagnostic for the quantitative determination of the chemotactic function of neutrophilic granulocytes
Clinical diagnostic for the quantitative analysis of leukocyte phagocytosis in human whole blood
Clinical diagnostic for the quantitative analysis of leukocyte oxidative burst in human whole blood
Clinical diagnostic for the quantification of the cytotoxic activity of human natural killer cells
Clinical diagnostic for the determination of the allergen-induced basophil degranulation
Research Reagent for the quantification of platelets-associated immunoglobulin
Research Reagent for the determination of reticulated platelets and low platelets count
*According to the EU’s in-Vitro Diagnostic (IVD) Directive